Cargando…

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

PURPOSE: To evaluate the safety, pharmacokinetics, and preliminary activity of bemarituzumab in patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA). PATIENTS AND METHODS: FPA144-001 was a phase I, open-label, multicenter trial consisting of the following 3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catenacci, Daniel V.T., Rasco, Drew, Lee, Jeeyun, Rha, Sun Young, Lee, Keun-Wook, Bang, Yung Jue, Bendell, Johanna, Enzinger, Peter, Marina, Neyssa, Xiang, Hong, Deng, Wei, Powers, Janine, Wainberg, Zev A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367551/ https://www.ncbi.nlm.nih.gov/pubmed/32167861 http://dx.doi.org/10.1200/JCO.19.01834

Ejemplares similares

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer
por: Xiang, Hong, et al.
Publicado: (2021)

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
por: Klempner, Samuel J., et al.
Publicado: (2019)

Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis
por: Klempner, Samuel J., et al.
Publicado: (2018)

Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial
por: Xiang, Hong, et al.
Publicado: (2020)

Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care
por: Sehdev, Amikar, et al.
Publicado: (2013)

Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials
por: Xiang, Hong, et al.
Publicado: (2021)

Crystal Structure of the SPOC Domain of the Arabidopsis Flowering Regulator FPA
por: Zhang, Yinglu, et al.
Publicado: (2016)

Transcription Termination and Chimeric RNA Formation Controlled by Arabidopsis thaliana FPA
por: Duc, Céline, et al.
Publicado: (2013)

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
por: Catenacci, Daniel V., et al.
Publicado: (2021)

The completeness of cancer registration in England: an assessment from the Oxford-FPA contraceptive study.
por: Villard-Mackintosh, L., et al.
Publicado: (1988)

FPA-FTIR Microspectroscopy for Monitoring Chemotherapy Efficacy in Triple-Negative Breast Cancer
por: Zawlik, Izabela, et al.
Publicado: (2016)

Widespread premature transcription termination of Arabidopsis thaliana NLR genes by the spen protein FPA
por: Parker, Matthew T, et al.
Publicado: (2021)

Analysis of Microplastics in Takeaway Food Containers in China Using FPA-FTIR Whole Filter Analysis
por: Zhou, Xuejun, et al.
Publicado: (2022)

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2019)

Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments
por: Gordon, Anderley, et al.
Publicado: (2022)

Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
por: Catenacci, Daniel V.T.
Publicado: (2014)

The RNA-binding protein FPA regulates flg22-triggered defense responses and transcription factor activity by alternative polyadenylation
por: Lyons, Rebecca, et al.
Publicado: (2013)

Understanding the structural degradation of South American historical silk: A Focal Plane Array (FPA) FTIR and multivariate analysis
por: Badillo-Sanchez, Diego, et al.
Publicado: (2019)

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
por: Bang, Yung-Jue, et al.
Publicado: (2019)

A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma
por: Benson, Al B., et al.
Publicado: (2017)

cmFPA008, an anti-mouse CSF-1R antibody, combines with multiple immunotherapies to reduce tumor growth in nonclinical models
por: Bellovin, David, et al.
Publicado: (2015)

SuFMoFPA: A superpixel and meta-heuristic based fuzzy image segmentation approach to explicate COVID-19 radiological images
por: Chakraborty, Shouvik, et al.
Publicado: (2021)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
por: Van Cutsem, Eric, et al.
Publicado: (2021)

A New Hybrid Model FPA-SVM Considering Cointegration for Particular Matter Concentration Forecasting: A Case Study of Kunming and Yuxi, China
por: Li, Weide, et al.
Publicado: (2017)

Beta and gamma ray studies of /sup 144/Cs, /sup 144/Ba and /sup 144 /La
por: Monnand, E, et al.
Publicado: (1976)

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
por: Bendell, Johanna C, et al.
Publicado: (2017)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients
por: Xu, Jianming, et al.
Publicado: (2023)

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
por: Kim, Sun Young, et al.
Publicado: (2017)

Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study
por: Ogata, Takatsugu, et al.
Publicado: (2023)

Protease-sensitive prions with 144-bp insertion mutations
por: Xiao, Xiangzhu, et al.
Publicado: (2013)

Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival
por: Chao, Joseph, et al.
Publicado: (2020)

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens
por: Wainberg, Zev A., et al.
Publicado: (2020)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease
por: Lee, Yeong Yeh
Publicado: (2013)

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
por: von Mehren, Margaret, et al.
Publicado: (2014)

Targeted Therapies for Metastatic Esophagogastric Cancer
por: Reddy, Deepa, et al.
Publicado: (2011)

144th LHCC Meeting
Publicado: (2020)

Zerfallsspektroskopie von $^{144}$Xe
por: Müller, Oliver
Publicado: (2013)

Hospital general 144 camas
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_1lp63hiu6e4ar4oeq5dtmnqbrt